our data suggest that the expansion of different T helper type 17 (Th17) phenotypes expressing TLR-2, -4 and -9 is associated with MS disease activity, and reveals a preferential ability of TLR-2 ligand in directly inducing the production of cytokines related to brains lesions and neurological disabilities.
Summary
Signalling through Toll-like receptors (TLRs) may play a role in the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). In the present study, the expression of TLR-2, -4 and -9 was significantly higher on CD4 + 
Introduction
Infectious diseases are implicated in the development and exacerbation of autoimmune diseases (AID), such as multiple sclerosis (MS), a T-cell-mediated demyelinated and neurodegenerative disorder of the central nervous system (CNS). [1] [2] [3] [4] Infections from influenza and herpesvirus families have been suggested as contributing agents to MS. Although infectious mononucleosis by Epstein-Barr virus (EBV) has been widely associated with MS development, this virus also appears to trigger other AID, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sj€ ogren's syndrome. [5] [6] [7] These observations suggest that in addition to molecular mimicry, bystander activation of the immune cells by microbial antigens may contribute to autoimmunity via breakdown of immunological tolerance in genetically predisposed individuals. In this context, some pathogen-associated molecular patterns (PAMPs), by playing an adjuvant role, have been implicated in MS pathogenesis. 8, 9 PAMPs mediate their effects through ligation to pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), mainly expressed on innate immune cells. 10 In humans, 10 different TLRs have been described, named 1-10, with different cellular distributions. While TLR-1, -2, -4, -6 and -10 are expressed on the cell surface, TLR-3, 
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-7, -8 and -9 are present intracellularly (e.g. endosomes).
11,12 TLR-1, -2, -4 and -6 recognize bacterial and fungal cell wall components, such as lipopolysaccharide (LPS) and lipopeptides, and TLR-5 binds flagellin. 10 In contrast, TLR-3, -7, -8 and -9 recognize nucleic acid structures, which serve as molecular signatures for viral and bacterial infections. 12 Upon PAMP engagement, the myeloid differentiation primary response protein 88 (MyD88), an adaptor protein associated with the majority of TLR, except TLR-3, activates nuclear factor (NF)-jb, which in turn trigger signalling cascades via phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/AKT) and Ras/mitogen-activated protein kinase (MAPK). These events promote cell survival and proliferation, as well as production of cytokines. 13 .
The reconnaissance of the involvement of PAMPs in MS comes from findings in the experimental model of multiple sclerosis, the experimental autoimmune encephalomyelitis (EAE). 14 The classical way of inducing EAE in mice is through the administration of myelin sheath antigens, such as myelin oligodendrocyte glycoprotein (MOG), emulsified in complete Freund's adjuvant (CFA), 14, 15 consisting of heat-inactivated Mycobacterium tuberculosis containing ligands for TLR-2, TLR-4 and TLR-9. 16 Additionally, the disease may also be induced by different PAMPs. 17 Prinz et al. 18 demonstrated that TLR-9-deficient mice exhibited a significant delay in the onset of EAE and milder clinical symptoms. Furthermore, knock-out mice for MyD88 are resistant to EAE induction. 18, 19 Finally, LPS injection induces relapses of EAE mice via bystander activation of myelin-specific CD4 + T-cells. 20 Altogether, these findings suggest that PAMP-induced DC maturation may contribute to the differentiation and expansion of encephalitogenic T-cells. TLRs might even influence on the conversion for progressive forms. 21 With regard to immune phenotypes, myelin-specific T helper type 17 (Th17) and Th1 cells have been implicated in the pathogenesis of MS. 22 High levels of interleukin-(IL)-17A mRNA are detected in the periphera|l blood and cerebrospinal fluid (CSF) of patients with relapsingremitting MS during clinical relapses. 23, 24 Further, the expression of IL-17 has been detected in astrocytes and oligodendrocytes in areas of active MS lesions. 24, 25 IL-17-producing CD8 + T-cells (Tc-17) also contribute to brain lesions. 26 With regard to interferon IFN-c, an important cytokine produced by both Th1 cells and Tc-1 cells, their levels are also elevated during clinical relapses, and colocalize with apoptotic oligodendrocytes. 27, 28 Although IL-22 is produced by human Th17 cells, the frequency of a unique subset of IL-22 producing CD4 + T-cells (Th22), regardless of IL-17 release, has been associated with apoptosis of oligodendrocytes, diminished expression of forkhead box protein 3 (FoxP3) and risk of new relapses and number of active brain lesions. [29] [30] [31] Finally, an increased proportion of granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting T CD4 + cells, some of these co-expressing IL-17 or IFN-c, were detected in the CNS of MS patients. 32, 33 Therefore, the ability of some PAMPs to up-regulate many co-stimulatory pathways in dendritic cells (DCs) may impact the risk of developing and exacerbating MS.
Although PPRs are classically expressed on innate immune cells, activated human T-cells also express detectable levels of TLRs, 15, 34 which suggests an ability of PAMPs to directly modulate the behaviour of T lymphocytes. 35 In SLE, elevated TLR-3 and -9 expression on Tcells is related to clinical parameters. 36 In MS patients, Nyirenda et al. 37 demonstrated an elevated TLR-2 expression on CD4 + CD25 hi FoxP3 + T-cells. The addition of TLR-2 agonist (Pam3Csk4) on regulatory T-cells (T regs ) not only inhibited their in-vitro suppressive actions, but also skews them towards a Th17 phenotype. 37 However, these authors did not evaluate the expression of TLRs on different T-cell phenotypes or correlate them with clinical parameters in MS patients, which are the objectives of the present study.
Material and methods

Patients
Thirty patients with a definite RRMS diagnosis, according to criteria (2010) 38 during the clinical remission phase, were recruited from Lagoa Hospital and Gaffr ee Guinle University Hospital/UNIRIO (Rio de Janeiro, Brazil). Demographic data such as gender and age at disease onset were obtained from medical records (Table 1 ). All patients were naive for disease-modifying therapies (DMT) and corticoid therapy for at least 2 months. The 39 To quantify the number of active brain lesions, some of the MS patients underwent brain magnetic resonance imaging (MRI) at the time of blood sampling and clinical evaluation. Imaging was performed using the Siemens Trio 3 Tesla machine. The sequences obtained were T1 GRE 3D (ECHO gradient) on the sagittal plane, with multiplanar reformatting before and after intravenous contrast, weighted sequences in T2 and proton density (PD), fluid attenuation inversion recovery (FLAIR) sequence and T1 magnetization transfer and dissemination with apparent diffusion coefficient (ADC) mapping in the axial plane. Images were analysed by a single neuroradiologist (F.R.), a specialist in demyelinating diseases and blind to the degree of the patient's disability. As a control group, 20 healthy subjects matched by age, gender and ethnic background were recruited. The study was approved by the Ethics Committee for Research on Human Subjects at the Federal University of the State of Rio de Janeiro (UNI-RIO) and blood was collected only after written informed consent was obtained from each individual.
Cultures
Peripheral blood mononuclear cells (PBMC) were separated by a Ficoll-Paque gradient. These cells were then washed three times in Hanks's balanced salt solution (HBSS) and suspended in RPMI-1640 medium supplemented with 2 lM of L-glutamine (Gibco, Carlsbad, CA), 10% of fetal calf serum, 20 U/ml of penicillin, 20 lg/ml of streptomycin and 20 mM of HEPES buffer. One 9 10 6 cells/ml of viable PBMC were cultivated in 24-well plates with 2 ml of complete medium in the presence or absence of anti-CD3/anti-CD28 beads (10 ll/ml) for 3 days at 37°a nd 5% CO 2 . In some experiments, enriched CD4 + and CD8 + T-cells were obtained via negative selection using magnetic columns, according to the manufacturer's instructions (EasySep TM ; StemCell Technology, Vancouver, Canada). Briefly, 50 ll of the isolation cocktail were added to a cell suspension of 1 9 10 7 cells in 1 ml of HBSS in a 14-ml tube. After rapidly mixing, the suspension was incubated for 10 min at room temperature. Then, 100 ll for CD4 + and 150 ll for CD8 + of the RapidSpheres suspension, already homogenated, were added to the cell suspension. After rapidly mixing, the cell suspension was incubated at room temperature for 5 min. Finally, 4 ml of HBSS was added to the cell suspension and, after pipetting, the tube was then placed at the magnet for 5 min. Finally, the supernatants were recovered. The purity of CD4 + Tcells and CD8 + T-cells was > 98%, as measured by flow cytometry (data not shown). Enriched CD4 + and CD8 + T-cell cultures were maintained for 48 hr in the absence or presence of TLR-4 agonist lipopolysacharide (LPS; 100 ng/ml) from Escherichia coli (Sigma-Aldrich, St Louis, MO)], TLR-2 agonist synthetic triacylated lipopeptide (Pam3Csk4, 1 lg/ml) from InvivoGen, San Diego, CA)] or TLR-9 agonist cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (ODN M362 1 lM/ml, from InvivoGen). These concentrations were chosen from a previous study conducted by Voo et al. 40 All cell cultures were kept for 48 hr at 37°and 5% CO 2 .
Immunofluorescence labelling and flow cytometry
The mouse anti-human monoclonal antibodies (mAbs) to CD3-phycoerythrin-cyanin 5 (PE-Cy5), CD8-fluorescein isothiocyanate (FITC), CD4-FITC, TLR-2-PE, TLR-4-PE, TLR-9-PE, IL-17A-PE-C7, IFN-c -allophycocyanin (APC), IL-6-APC, IL-10-APC and all isotype-control antibodies were purchased from BD Bioscience (San Diego, CA), and were used to quantify the percentage of different T-cell subsets. Briefly, various combinations of mAbs directed for surface markers were added to PBMC (2 9 10 5 /tube) and incubated for 30 min at room temperature in the dark. The cells were washed with phosphate-buffered saline (PBS), then permeabilized by incubating cells with Cytofix/Cytoperm (BD Pharmingen, San Diego, CA) at 4°for 20 min. After washing, the antibodies for intracellular staining (anti-IL-17, anti-IFN-c, anti-IL-10, anti-IL-6) or the corresponding isotype control anti-immunoglobulin (Ig)G1 were added in various combinations and incubated for 30 min at 4°. The cells were analysed in the Accuri C6 (Accuri TM ; Ann Arbor, MI) and CFlow software (Accuri TM ; Ann Arbor). Isotype control antibodies and single-stained samples were used to periodically check the settings and gates on the flow cytometer. After acquisition of 200 000 events, lymphocytes were gated based on forward-and side-scatter properties after the exclusion of dead cells by using propidium iodide and doublets. Further, the gated cells were negative for CD14 marker.
ELISA technique
After 48 hr, the supernatant from PAMP-activated CD4 + and CD8
+ T-cells were collected and the cytokines were quantified by enzyme-linked immunosorbent assay (ELISA) using OptEIA ELISA kits (BD Pharmigen, San Diego, CA), according to the manufacturer's instructions. Briefly, each ELISA was performed using pairs of antibodies against IL-1b, IL-6, TNF-a, IL-17A (IL-17), IL-22, GM-CSF and IL-10. The reaction was revealed with streptavidin-horseradish peroxidase, using 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) as substrate. Recombinant human cytokines, at concentrations ranging from 3Á5 to 500 pg/ml, were used to construct standard curves.
Statistical analysis
Statistical analysis was performed using PRISM version 5Á0 software (GraphPad Software). All immunological evaluations were performed in triplicate or quadruplicate in each individual and the intra-assay variability ranged from 8Á7 to 15Á1% (median value of 10Á1%), as calculated by the software. The non-parametric Mann-Whitney Utest and Student's t-test were applied to determine whether the two groups were statistically different for non-parametric and parametric variables, respectively.
Correlations between variables were investigated using Pearson's correlation. The significance in all experiments was defined as P < 0Á05.
Results
Clinical and demographic data
Our study was performed with 30 MS patients, nine males (30%) and 21 females (70%), all in remission phase ( Table 1 ). The mean age at disease onset was 27Á7 years (range 17-38 years). Mean time between MS diagnosis and blood sampling was approximately 5Á2 years (range 1-13 years). All 30 patients were naive for disease-modifying therapies (DMT); 70% of patients had been previously treated with oral or intravenous corticosteroids to control the acute neurological bouts. However, at the time of the study none of these patients were on corticosteroids for 60 days. Despite all patients being clinically asymptomatic, at the moment of evaluation the data from the brain MRI scan revealed that 18 patients (60%) had active lesions (Table 1) .
TLR expression on T-cells from MS patients and the cytokine profile
Following the gating strategy shown in Fig. 1a ,b, we observed that TLR-2, -4 and -9 expression was significantly higher at the basal level in both CD4 + and CD8 + T-cells from MS patients than in healthy controls (Fig. 1c,d) . Moreover, as shown in Supporting information, Fig. S1 , in MS patients the expression levels of TLR-2, TLR-4 and TLR-9 were significantly higher in Supporting information, S2a-d) and CD8 + ( Fig. 2b and Supporting information, S3a-d) T-cells from MS patients. Moreover, with regard to other cytokines, the proportion of IL-6-producing CD4 + and CD8 + T-cells positive for TLR-2, -4 and -9 was also higher in MS samples when compared with control (Fig. 2a,b) . No significance was observed in the percentage of TLR + (-2, -4 and -9) CD4 + T-cells capable of producing IFN-c or IL-10 between MS patients and controls (Fig. 2a) . By contrast, a higher proportion of IFN-c + TLR + CD8 + T-cells were observed in patients with MS (Fig. 2b) . The proportions of TLR + CD8 + T-cells positive for IL-10 were almost undetectable in majority of patents and controls subjects (Fig. 2b) . Among T-cells negative for TLR-2, -4 and -9, detectable cytokine production was seen only after cell activation (Fig. 2b and 2b) . While the percentage of activated peripheral IL-6-secreting TLR À (CD4 and CD8) T-cells were significantly higher in patients, a significantly higher proportion of activated IL-17 + TLR À T-cells was observed only in the MS-derived CD8 + compartment (Fig. 2b) . In contrast to TLR-positive subsets, the percentage of TLR À (CD4 and CD8) T-cells able to produce IFN-c and IL-10 was significantly lower in the patient sample (Fig. 2a,b) .
The proportion of IL-6-and IFN-c-producing TLR + IL-17 + T-cells was associated with clinical parameters in MS patients Although IL-17 is the signature cytokine of the Th17 phenotype, these CD4 + T-cells present a functional heterogeneous lineage, which may perform antagonistic functions. [41] [42] [43] [44] The percentage of Th17-like subsets able to produce IL-17 along with IFN-c or with IL-6 was significantly higher among CD4 + and CD8 + T-cells positive for TLR-2, -4 and -9 in MS patients than in the control group (Fig. 3b) . No significant difference was observed in terms of dual IL-10-and IL-17-secreting T-cells. Moreover, in MS patients, the proportion of IL-6-secreting IL-17 + TLR + (-2, -4 and -9) T-cells, either CD4 or CD8 cells, was significantly higher than those able to co-produce IFN-c or IL-10 ( Fig. 3a,b) . In our previous study, IFN-c + IL-17 + CD4 + or CD8 + T-cell frequencies were positively associated with neurological disabilities, as determined by Expanded Disability Status Scale (EDSS) score. 44 The T-cells, were positively correlated with radiological activity of the disease and neurological disabilities (Table 2) . Nevertheless, taking into consideration the Pvalues, in general a stronger correlation was observed between the frequency of IFN-c + IL-17 + TLR + T-cell subsets and the number of active brain lesions, mainly those positive for TLR-2. No correlation was observed between clinical parameters and dual IL-17 and IL-6-producing (CD4 + and CD8 + ) T-cells negative for TLR-2, -4 and -9 (data not shown). Furthermore, no correlation was seen between these signs of clinical activity of the disease and the proportion of all IL-17-secreting T-cell subsets when maintained with medium alone (data not shown). The levels of IL-6, IL-17, IFN-c and GM-CSF released by purified T-cells were correlated with disease activity
The ability of T-cells to express TLR-2, -4 and -9 suggests that those cells may directly respond to agonists for these PRRs. As observed in Fig. 4 , the Pam3Csk4 (TLR-2L), LPS (TLR-4L) and ODN (TLR-9L) were able to directly induce cytokine production by purified CD4 + and CD8 + T-cells from MS patients. Among the PAMPs, Pam3Csk4 was more potent at inducing the production of all proinflammatory cytokines by CD4 + T-cell cultures (Fig. 4a) . Moreover, the production of IL-1b, IL-6 and IL-17 by Pam3Csk4-activated CD8 + T-cells was higher when compared with LPS and ODN. In terms of IL-10, its production was elevated in CD4 + and CD8 + T-cells after addition of LPS. More importantly, the number of active brain lesions and EDSS scores were positively associated with IL-6 levels produced by CD4 + and CD8 + T-cells in response to LPS and Pam3Csk4 (Table 3) . Further, the release of IFN-c and IL-17 by CD4 + T-cells, as well as IL-17 from CD8 + T-cells, in response to Pam3Csk4 was directly correlated with clinical parameters (Table 3) . Finally, CD4 + T-cells from patients with the highest number of brain lesions responded in vitro to Pam3Csk4 stimulation, releasing higher GM-CSF levels ( immunological tolerance via activation of self-reactive Tcells. 8, 15, 17, 18, 45 In the present study, we demonstrated a relationship between elevated TLR-2, -4 and -9 expression on IL-17-secreting T-cell subsets and disease severity in MS patients.
In MS, the TLR engagement by different PAMPs on DCs appears to favour both Th1 and Th17 phenotypes by releasing high levels of IL-12 and IL-23, respectively. 45 Activated human T-cells also express TLRs, and studies suggest that TLR ligands may result in a lower threshold for T-cell reactivation via TCR. 35, [46] [47] [48] In the present study, the frequency of CD4 + and CD8 + T-cells expressing TLR-2, -4 and -9 was higher in MS patients than healthy individuals, even in the absence of stimulus. Of note, a higher percentage of those TLR + T-cells in patients was also observed ex vivo, i.e. after immediate staining of blood sampling (data not shown). In the future, we hope to evaluate the expression of other types of TLRs.
In EAE, CD4 + T-cells deficient in TLR-2 expression were partially protected from experimental autoimmune encephalomyelitis. 49, 50 In humans, TLRs are involved in the pathogenesis of others Th17-mediated autoimmune diseases, such as SLE, 51 rheumatoid arthritis 52 and neuromyelitis optic spectrum disorder. 53 A recent study by Zastepa et al. 54 demonstrated sustained TLR-2 and -4 expression on naive CD4
+ T-cells following in-vitro polyclonal activation in MS patients who evolved rapidly to the progressive form of the disease. These findings suggest the involvement of TLR expression in T-cells in MS pathogenesis.
In the present study, although elevated expression of TLR-2, -4 and -9 on MS-derived T-cells was not correlated per se with clinical parameters (data not shown), IL-17 + IL-6 + and IL-17 + IFN-c + among TLR + CD4 + and CD8 + T-cell subsets directly correlated with the number of active brain lesions and neurological disabilities, as determined by EDSS score. These data suggest an involvement of different Th17-like phenotypes in MS.
It is well recognized that IL-17-secreting T-cells present a functional heterogeneous lineage. Among CD4 + T-cells, some pathogenic human Th17 cell subsets have been identified through co-expression of CCR6 and CXCR3 and simultaneous production of cytokines IL-17 and IFN-c. 55 The differentiation of this T-cell subset depends upon IL-6, IL-1b and IL-23 associated with an absence of transforming growth factor (TGF)-b. [55] [56] [57] [58] Upon transfer, these IFN-c-secreting Th17 cells induced more severe 
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EAE than those that received the classical Th17 cells. 55 Although these cells present a minor T-cell phenotype among those that secrete IL-17 or IFN-c, they were found in the blood and CSF from MS patients during clinical relapses. 23 Moreover, in our previous study, a proportion of total IFN-c + IL-17 + (CD4 + and CD8 + ) T-cells was associated with EDSS score. 44 These data suggest that circulating IL-17 + IFN-c + T-cells, regardless of expression of TLR-2, -4 and -9, may present pathogenic phenotypes in MS. Furthermore, to the best of our knowledge, we report for the first time an expansion of IL-17 + IL-6 + TLR + T-cells that was associated with MS severity. It is known that knock-out mice for IL-6 are resistant to EAE induction. 59 Ferreira et al. 60 also demonstrated that endogenous IL-6 is important to maintain the production of IL-17 by CD4 + T-cells from MS patients, as well as its role in favouring Th17 phenotype differentiation. Further, excess of IL-6 damaged T reg cells function through reduction of FoxP3 protein expression and release of IL-10, a potent anti-inflammatory cytokine. 61, 62 In the present study, the percentage of IL-10 + (CD4 + and CD8 + ) T-cells negative for TLR-2, -4 and -9 was significantly lower in patients; however, no relationship was observed with clinical parameters (data not shown). Nevertheless, there is a possibility that, in vivo, excessive production of IL-6 by different T-cell subsets co-stimulated with different TLR ligands may overcome T reg -mediated suppression of encephalitogenic T-cells. Nyirenda et al. 37 showed that TLR-2 ligand Pam3Csk4 and TLR-4 ligand LPS directly blocked anti-CD3-activated T reg cell function by reducing IL-10 production, and by inducing resistance in effector Tcells to T reg suppression. In general, these results suggest that PAMPs, via different mechanisms, may play a pathogenic role in autoimmunity. With regard to IFN-c, no difference was observed in the total IFN-c-secreting CD4 + and CD8 + T-cells between the two experimental groups (data not shown). Nevertheless, the IFN-c-producing (CD4 + and CD8 + ) T-cells negative for TLR-2, -4 and -9 were significantly lower in MS patients than in healthy subjects, which may be a consequence of a trend of higher percentage of IFN-c-secreting TLR + T-cell subsets. Although PAMPs co-stimulate T-cell activation, in the present study we have demonstrated that TLR-2, -4 and -9 can directly induce cytokine production by purified CD4 + T and CD8 + T-cells from MS patients. In general, among PAMPs, Pam3Csk4, a TLR-2 ligand (TLR-2L), was more potent in inducing the production of all proinflammatory cytokines by CD4 + T-cell cultures. Moreover, the production of IL-1b, IL-6 and IL-17 by Pam3Csk4-activated CD8 + T-cells was higher when compared with LPS and ODN. In contrast, the Pam3Csk4 induced almost no IL-10. These findings are in agreement with reported studies demonstrating the ability of Pam3Csk4 to promote production of proinflammatory cytokines by memory T-cells from healthy individuals and MS patients, whereas it inhibits IL-10 production by T reg cell subsets. 37, 40, 46, 49 When we correlate the cytokine content and clinical parameters, IL-6 levels produced by CD4 Figure 4 . Cytokine production by T-cells from multiple sclerosis (MS) patients in response to pathogen-associated molecular patterns (PAMPs). The cytokine content in the supernatants collected from purified CD4 + (a) and CD8 + T-cell (b) cultures maintained for 2 days in the absence or presence of lipopolysaccharide (LPS) (100 gg/ml), Pam3Csk4 (1 lg/ml) and oligodeoxynucleotide (ODN) (1 lM/ml) was determined using enzyme-linked immunosorbent assay (ELISA). In the figure, (*), (**) and (***) indicate P-values < 0Á05, < 0Á001 and < 0Á0001. The presence of GM-CSF + T-cell phenotypes have been associated with disease activity in both EAE and MS. 32, 33 This haematopoietic factor should contribute to neuronal damage by inducing recruitment and activation of monocytes into the CNS. 65 Here, the ability of TLR-2L to induce the production of GM-CSF by CD4
+ T-cells reinforced the adverse impact of infections in MS.
While TLR-4 and -9 recognize LPS and DNA from bacteria and virus, respectively, TLR-2 is required for recognition of diverse microbial molecules from various types of microorganisms, such as Gram-positive bacteria rich in TLR-2 ligands and Clostridium perfringens, recently associated with NMOSD, another CNS neurodegenerative autoimmune disease. 66, 67 Interestingly, dysbiosis with overgrowth of commensal species belonging to the Clostridia cluster has been reported in MS patients. 68 Excessive TLR-2 ligands from these bacteria are known to induce colitis in animal models of inflammatory bowel disease. 69 These findings suggest the adverse impact of microbial translocation in MS. In this context, a study published by our group 70 demonstrated elevated plasma levels of LPS in MS patients, which were directly related to in-vivo IL-6 production. Finally, the presence of endogenous TLR ligands, called danger-associated molecular patterns (DAMPs), could also contribute to MS. In MS, heat shock protein (HSP)70 is a DAMP highly expressed on brain lesions 71 that binds to myelin basic protein, forming a immunogenic complex 72 able to influence the induction of EAE. 73 Although further studies are required, these findings suggest that infections or events that elevate intestinal translocation of bacteria should impact upon the progression of MS by favouring the activation of encephalitogenic memory TLR + Th17 cell subsets, both directly and indirectly, through release of alarmins (DAMPs) from damaged cells during inflammatory reactions against pathogens and/or their PAMPs.
Conclusions
In conclusion, our data, although preliminary, suggest that the expansion of different Th17/Tc-17-like phenotypes expressing TLR-2, -4 and -9 are associated with MS severity, and reveal a particular ability of the TLR-2 0Á4414  0Á4333  0Á5909  0Á2444  IFN-c  0Á3928  0Á6667  0Á4045  0Á6661  IL-17  0Á3816  0Á6605  0Á4112  0Á6567  IL-22  0Á3928  0Á6645  0Á4043  0Á6661  GM-CSF  0Á3921  0Á6660  0Á4045  0Á6667  IL-10  0Á2310  0Á65  0Á1941  0Á7722  TLR-2 agonist  IL-1b  0Á2571  0Á6583  0Á4414  0Á4111  IL-6  0Á8407  0Á0444  0Á8359  0Á0667  TNF-a  0Á5161  0Á3333  0Á4690  0Á3101  IFN-c  0Á6761  0Á2  0 Á6093  0Á2667  IL-17  0Á9429  0Á0167  0Á9122  0Á022  IL-22  0Á1309  0Á6667  0Á435  0Á3339  GM-CSF  0Á4395  0Á4 ligand to directly induce cytokine production related to brain lesions and neurological disabilities. This study is significant, because we believe that our data highlight possible molecular mechanisms by which microorganisms negatively impact autoimmunity, which could help to design immunotherapeutic tools for MS patients.
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